Chromosome region maintenance 1 (CRM1) mediates the nuclear export of proteins and mRNAs, and is overexpressed in various cancers. Recent studies have also reported that CRM1 protein expression is a negative prognostic factor in patients with cancer. Therefore, CRM1 is considered a potential target for anticancer therapy. Our previous study demonstrated that CBS9106, a synthetic small-molecular inhibitor of CRM1, decreases CRM1 protein through proteasomal degradation without affecting CRM1 mRNA levels. However, the mechanism by which CRM1 is degraded is not well understood. Here, we demonstrate a novel signaling pathway that plays an important role in CBS9106-induced CRM1 degradation. We found that MLN4924, a selective inhibitor of NEDD8-activating enzyme (NAE), effectively inhibits cullin neddylation and attenuates CBS9106-induced CRM1 degradation in a time-and dose-dependent manner. MLN4924 also attenuated CBS9106-induced nuclear accumulation of Ran-binding protein 1 (RanBP1), cell growth inhibition, and apoptosis. Furthermore, RNAi-mediated knockdown of neddylation pathway proteins (NEDD8 and UBA3) or cullin ring ligase (CRL) component protein (Rbx1) attenuated CRM1 protein degradation and G 1 phase cellcycle arrest by CBS9106. Knockdown of CSN5 or CAND1 also partially inhibited CBS9106-induced CRM1 degradation. These findings demonstrate that CBS9106-induced CRM1 degradation is conferred by CRL activity involving the neddylation pathway, and that this response to CBS9106 leads to cell growth inhibition and apoptosis. Mol Cancer Ther; 13(12); 3013-23. Ó2014 AACR.
Introduction
Chromosome region maintenance 1, CRM1, was originally identified in yeast as a gene required for maintaining chromosome structure (1) . CRM1 protein is now known to be a nuclear export receptor belonging to the karyopherin b family of transport receptors (2) . CRM1 binds to different cargo proteins bearing leucine-rich nuclear export sequences leading to nuclear export of cargo proteins and mRNAs (3, 4) . Exported cargo proteins include tumor suppressors, such as p53, BRCA1, survivin, nucleophosmin, and adenomatous polyposis coli that shuttle between the nucleus and cytoplasm (5) . CRM1 is overexpressed in various malignancies, such as breast, cervical, ovarian, and pancreatic cancers, glioma, and osteosarcoma (6) . Knockdown of CRM1 protein via siRNA causes cell growth inhibition and apoptosis in cancer cells, whereas normal tissues are unaffected by CRM1 downregulation (7) . Thus, CRM1-mediated nuclear export is considered a potential target for treating cancers.
The natural product leptomycin B (LMB) was identified as the first specific inhibitor of CRM1 (8) . LMB binds covalently to a specific cysteine residue on CRM1 (Cys528), prevents complex formation between CRM1 and cargo proteins, and effectively blocks nuclear export of cargo proteins (9) . LMB exhibits strong antitumor activity in vitro against various cancer cells; however, a phase I trial of LMB had to be discontinued because of significant toxicity and apparent lack of efficacy (10, 11) .
We have identified CBS9106 as a novel CRM1 inhibitor that, unlike LMB, contributes to CRM1 protein degradation without affecting CRM1 mRNA levels. CBS9106-induced CRM1 protein degradation was counteracted by bortezomib, indicating that a proteasomedependent degradation pathway was involved in the process (12) . Subsequently, CRM1-selective inhibitors of nuclear export, such as KPT-185 and KPT-330, were reported by some groups in collaboration with Karyopharm therapeutics (13) (14) (15) . Like CBS9106, both KPT-185 and KPT-330 induce proteasome-dependent CRM1 protein degradation, but both also promoted CRM1 mRNA expression (14) .
The ubiquitin-proteasome system regulates diverse biologic processes by controlling the degradation rates of various cellular proteins (16, 17) . Proteasome inhibition is recognized as a novel therapeutic approach for human cancer and several proteasome inhibitors have been developed for this purpose, including bortezomib, carfilzomib, and MG132 (18, 19) . In particular, bortezomib was the first to enter clinical use (20) . Carfizomib, a secondgeneration proteasome inhibitor that is structurally and mechanistically different from bortezomib, has also been approved for treatment of patients with relapsed/refractory multiple myeloma (21) .
Neddylation is a process of protein modification by the ubiquitin-like NEDD8 protein and is one of the pathways that lead to proteasome-dependent protein degradation. The cullin family of E3 ubiquitin ligase scaffolds has been characterized as the major class of substrates for neddylation. Neddylation is required for conformational changes in cullin that are necessary for regulating the activity of cullin ring ligases (CRL). The components of the neddylation pathway include NEDD8-activating enzyme E1 (NAE), NEDD8-conjugating enzyme E2 (Ubc12), and NEDD8 E3 ligase. MLN4924 was recently discovered as a first-in-class, potent, and selective inhibitor of NAE and is currently in phase I clinical trials for both solid tumor and hematologic malignancies (22, 23) .
CRLs are the largest family of E3 ubiquitin ligases targeting approximately 20% of ubiquitinated protein substrates for 26S proteasomal degradation (22) . CRLs consist of multisubunits containing cullin (Cul 1, 2, 3, 4A, 4B, 5, and 7) and the RING-finger protein Rbx (24) . CRL activity is regulated in vitro by the highly conserved COP9 signalosome (CSN) protein complex and by cullin-associated and neddylation-dissociated protein 1 (CAND1; refs. [25] [26] [27] . Neddylation is reversed by the eight-subunit CSN complex (CSN1-CSN8) via specific isopeptidasedependent cleavage of NEDD8 from the cullin subunit of CRLs (25) . CAND1 binds to the unneddylated form of all cullins and inhibits E3 ligase activity of CRL (28, 29) . However, depletion of CSN or CAND1 from cells leads to decreased CRL function (25) . These apparent paradoxes were reconciled by some several reports. Certain groups have proposed that depletion of CSN prevents cleavage of NEDD8 from cullins and that the resulting NEDD8-activated cullins induce degradation of several F-box proteins (30) (31) (32) . Other groups have proposed that depletion of CAND1 prevents displacement of Skp1 from cullins, and thereby prevents new F-box proteins from being recruited to preexisting cullins (33) (34) (35) .
In this study, we have identified that CBS9106 induces CRL activity involving the neddylation pathway, and thereby degradation of CRM1 protein.
Materials and Methods

Cell lines and reagents
Human colon carcinoma cell lines, HCT116 (p53 wt, CCL-247), HT29 (p53 mt, HTB-38), HCT15 (p53 mt, CCL-225), RKO (p53 wt, CRL-2577), and RKO/E6 (functional p53-deficient, CRL-2578) were purchased from the ATCC. Cell lines were authenticated by short tandem repeat analysis. Cell lines were initially grown and low passage stocks were cryopreserved in liquid nitrogen. Cells were replaced from frozen stocks after 3 months continuous culture. HCT116 and HT29 cells were cultured in McCoy 5a medium (Gibco Life Technologies) containing 10% FBS (Gibco Life Technologies) and 1% penicillin/streptomycin (PS; Gibco Life Technologies). HCT15 cells were cultured in RPMI-1640 medium (Sigma-Aldrich) containing 10% FBS, 1% PS, 10 mmol/L Hepes, 1 mmol/L sodium pyruvate (Sigma-Aldrich), and 4.5 g/L D-glucose. RKO and RKO/E6 cells were cultured in Minimum Essential Medium Eagle (Sigma-Aldrich) containing 10% FBS, 1% PS, 1 mmol/L sodium pyruvate, and 2 mmol/L L-glutamine (Sigma-Aldrich). The cells were grown at 37 C in humidified atmosphere consisting of 5% CO 2 and 95% air. CBS9106 was manufactured by Mercachem. MLN4924 was purchased from Active Biochem. LMB was purchased from Santa Cruz Biotechnology. Bortezomib was purchased from Selleck Chemicals. MG132 and 3-Methyladenine (3-MA) were purchased from Calbiochem. Bafilomycin A1 was purchased from Sigma-Aldrich.
Cell extracts and Western blot analysis
To prepare extracts from cell culture, cells were washed with PBS and resuspended in lysis buffer [20 mmol/L Tris-HCl (pH 8), 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 0.5% (v/v) Nonidet P40, complete protease inhibitor cocktail (Roche), PhosSTOP phosphatase inhibitor cocktail (Roche)]. Cells were vortexed with periodic cooling on ice for 1 hour and then centrifuged at 13,000 rpm for 10 minutes (4 C). Cell extracts were resuspended in a loading buffer and stored at À80 C until analysis by SDSPAGE and Western blotting. Proteins were separated by electrophoresis on the Mini-protean TGX gel (Bio-Rad) and transferred to Immobilon-P polyvinylidene difluoride membranes (Millipore). Antibodies against CRM1 (H300), CyclinB1 (H433), Ub (P4D1), UBA3 (E5), CAND1 (TIP120A, A13), Skp2 (H435), p27 (F8), or b-actin (C4) were purchased from Santa Cruz Biotechnology. Antibodies against NEDD8 (2754), p53 (9282), LC3-I/ II (12741), SUMO-1 (4930), SUMO-2/3 (4971), Rbx1 (4397), CSN5 (COPS5, 6895), and rabbit IgG, as well as mouse IgG conjugated with horseradish peroxidase, were purchased from Cell Signaling Technology.
Cell viability and cell growth assays HCT116 cells (2 Â 10 3 ) were seeded on 96-well plates and incubated for 24 hours. After incubation with CBS9106, LMB, or MLN4924, cell viability and cell growth were analyzed with a Cell Counting Kit-8 (Dojindo). Reagent solution was added to each well, the 96-well plates were incubated for 3 hours at 37 C, and the absorbance at 450 nm (OD 450 ) was measured using a Sunrise basic microplate reader (Tecan Austria GmbH), in accordance with the manufacturer's instructions.
Cell-cycle analysis
HCT116 cells were washed in PBS and harvested with trypsinization. Cells were stained in propidium iodide/ RNase buffer and analyzed by FACSCalibur flow cytometer using CellQuest software (Becton Dickinson). Annexin V-FITC (Trevigen) was used to stain apoptotic cells.
Immunofluorescence
Approximately 5 Â 10 3 cells were seeded onto CELLview glass bottom dishes (Greiner Bio-One) and grown overnight at 37 C. Cells were treated with CBS9106 (100 nmol/L), LMB (0.5 nmol/L), and/or MLN4924 (50 nmol/L) at 37 C for 24 hours. Cells were fixed with 4% paraformaldehyde phosphate buffer solution (Wako) for 30 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 15 minutes and then blocked with 4% Block Ace (DS Pharma Biomedical) for 1 hour at room temperature followed by specific antibody treatment. Goat-anti-RanBP1 antibodies (C19; Santa Cruz Biotechnology) or Goat-anti-CRM1 antibodies (C20; Santa Cruz Biotechnology) were used at a 1:50 dilution. Alexa488-conjugated donkey anti-goat antibodies (Molecular Probes Life Technologies) were used at a 1:500 dilution. Cellular DNA was stained with 1 mg/ mL Hoechst33342 (Dojindo). The stained cells were visualized on a FluoView FV10i confocal microscope (Olympus) equipped with a Â60 oil immersion lens. Images were processed using FV10-ASW (Version 2.1) software (Olympus). ) were resuspended in 100 mL of the Cell Line Solution Kit V (Lonza). One mmol/L siGEN-OME SMARTpool siRNA (Dharmacon) was added and the cells were immediately transfected using the Nucleofector device (Lonza; program D-032). Of note, 2 mL of the preequilibrated culture medium was then added and the cells were cultured in the 6-well plate for 48 or 72 hours. Target gene-specific siRNAs were obtained from Dharmacon as follows: NEDD8 (M-020081), UBA3 (M-005249), RBX1 (M-004087), CSN5 (COPS5, M-005814), CAND1 (M-015562), and siGENOME Nontargeting siRNA Pool (D-001206).
Statistical analysis
Data were analyzed using the t test (Student t test or Welch t test). Data are expressed as the mean AE SD. A P value of <0.05 was considered significant.
Results
MLN4924 prevents CBS9106-induced CRM1 reduction
CBS9106 is a CRM1 inhibitor identified through cellcycle-based phenotypic screening (Fig. 1A) . CBS9106 treatment leads to reduction of CRM1 protein through a proteasome-mediated degradation pathway. However, the detailed mechanism responsible for CRM1 degradation is unclear. In this study, we focused on the neddylation pathway involving CRL activity. Experiments were performed using MLN4924, a specific NAE inhibitor that blocks this first step of the neddylation pathway. HCT116 cells were treated with CBS9106, and the levels of CRM1 protein were analyzed by Western blotting using an anti-CRM1 antibody. As previously reported (12) and as shown in Fig. 1B , 100 nmol/L CBS9106 decreased CRM1 protein expression in a time-dependent manner. Decreased levels of CRM1 protein were clearly observed at 4 to 8 hours of treatment (lanes 3-5). In contrast, a similar decrease was not observed upon concomitant treatment with MLN4924 (lanes 8-10). MLN4924 targets the neddylation pathway, which is upstream of the 26S proteasome in the ubiquitin-proteasome pathway (36) . As shown in lanes 6 to 10 in Fig. 1B , neddylation of cullin was inhibited by MLN4924, even at the shortest exposure time (2 hours, lane 7). The expression level of p53, one of the cargoes of CRM1, was increased upon treatment with CBS9106 alone (lanes 3-5) or with CBS9106 plus MLN4924 (lanes [8] [9] [10] . Figure 1C shows the dose-dependent effects of MLN4924 in preventing the reduction of CRM1 by CBS9106 in HCT116 cells. The expression of CRM1 protein was significantly reduced by treatment for 24 hours with 100 nmol/L CBS9106 (lane 6). In contrast, the CBS9106-induced decrease in CRM1 was attenuated with 5 nmol/L MLN4924 (lane 8), the concentration at which decreased neddylation of cullins began to appear. The levels of p53 were increased by treatment with 50 nmol/L MLN4924 (lane 5). However, stabilization of p53 by CBS9106 was modestly decreased by 5 and 10 nmol/L MLN4924 (lanes 8 and 9).
Similar results were obtained with MM.1S multiple myeloma cells, a cell line more sensitive to CBS9106 treatment than HCT116 (Supplementary Fig. S1 ). Treatment of MM.1S cells with MLN4924 also inhibited the accumulation of cleaved PARP, an apoptosis marker that increases in the presence of CBS9106.
MLN4924 is known to selectively inhibit NAE relative to related enzymes, such as SUMO-activating enzyme and ubiquitin-activating enzyme (22) . Therefore, these findings indicate that CBS9106-induced CRM1 degradation is conferred by the NAE-mediated neddylation pathway.
CBS9106-induced CRM1 degradation is dependent on the neddylation pathway, but not on autophagy/ lysosome or p53
To investigate the degradation pathway of CRM1 by CBS9106, HCT116 cells were treated with various inhibitors, including MLN4924, ubiquitin-proteasome inhibitors (MG132 and bortezomib) and autophagy/lysosome inhibitors (3-MA and bafilomycin A1). As shown in Fig. 2A, MLN4924 , MG132, and bortezomib inhibited CBS9106-induced CRM1 degradation. In addition, the results show that MLN4924 treatment was not associated with increases in polyubiquitinated signals as compared Fig. 2A, lanes 3-8) .
In contrast, 3-MA and bafilomycin A1 did not inhibit CRM1 degradation by CBS9106 ( Fig. 2A and Supplementary Fig. S6 ). Disruption of autophagy can be induced either before (3-MA) or after (bafilomycin A1) the LC3-I to LC3-II conversion. Furthermore, p62 protein is a useful marker for the induction of autophagy (37) . As shown in Supplementary Fig. S6 , 3-MA treatment prevented p62 reduction. These results indicate that CBS9106-induced CRM1 degradation depends on a neddylation and not on autophagy.
Inhibition of CBS9106-induced CRM1 degradation by MLN4924 was also confirmed in the HT29 and HCT15 colon cancer cell lines (Fig. 2B ). As shown in Fig. 2B , CBS9106-induced stabilization of p53 was reduced by MLN4924. Therefore, CRM1 degradation appears to be important for the CRM1 inhibitory activity of CBS9106. To confirm this hypothesis, we analyzed the effect of MLN4924 on p53 stabilization caused by CRM1 inhibitors. Treatment of RKO cells with CBS9106 led to stabilization of p53 protein that could be inhibited by MLN4924 (Fig. 2C) . Another CRM1 inhibitor, LMB also led to the stabilization of p53 protein, but this stabilization increased further upon addition of MLN4924 (Fig. 2C) . As expected, stabilization of p53 protein was not found in RKO/E6 cells (Fig. 2C ). These results using two different CRM1 inhibitors show that the inhibitory effect of MLN4924 is specific to CBS9106 and further support the importance of CRM1 degradation to the activity of CBS9106.
Inhibition of neddylation partially protects HCT116 cells from CBS9106-induced cell growth inhibition and apoptosis
The effect of CBS9106 and MLN4924 on the cell viability and growth of HCT116 cells was evaluated by the Cell Counting Kit-8. In this experiment, the dose of MLN4924 was decreased from 50 to 10 nmol/L to avoid the induction of apoptosis observed at the higher concentration. A single treatment with 10 nmol/L of MLN4924 inhibited neddylation of cullins without inducing apoptosis, whereas 50 nmol/L of MLN4924 alone induced apoptosis (subG 1 17.0%) starting at 72 hours ( Supplementary Fig. S2 ). MLN4924 induces DNA damage and apoptosis through DNA re-replication (38, 39). In this context, treatment with 50 nmol/L MLN4924 for 72 hours increased DNA content greater than 4-fold ( Supplementary Fig. S2 ). The viability of HCT116 cells at 72 hours was significantly reduced by 100 nmol/L CBS9106, but recovered from 24.9% to 61.3% upon adding 10 nmol/L MLN4924 (Fig. 3A) . In contrast, LMB, which does not reduce CRM1 protein, leads to a reduction of cell viability that was not reversed by the addition of MLN4924 (Fig. 3B) . The inhibition of cell growth by 100 nmol/L CBS9106 was partially rescued by adding 10 nmol/L MLN4924, with the degree of rescue increasing steadily over time (Fig. 3C) . However, the inhibition of cell growth by 0.5 nmol/L LMB was not rescued by adding 10 nmol/L MLN4924.
Cell-cycle distribution was evaluated by flow cytometry with the subG 1 population reflecting the induction of apoptosis. The subG 1 fraction increased to 29.3% after 72 hours with 200 nmol/L CBS9106 treatment, but was reduced to 17.4% by adding 10 nmol/L MLN4924 (Fig.  3D) . In contrast, cotreatment of 0.3 nmol/L with 10 nmol/ L MLN4924 tended to enhance apoptosis. Similar pattern was obtained using FITC-labeled Annexin V (Fig. 3E) . Results similar to those for HCT116 were obtained for MM.1S ( Supplementary Fig. S3 ), HT29, and HCT15 (Supplementary MLN4924 attenuates the effects of CBS9106 on cell growth inhibition and cell death.
Nuclear localization of RanBP1 by CBS9106 is prevented by MLN4924 Ran-binding protein 1 (RanBP1) shuttles between the nucleus and cytoplasm, but is predominantly localized to the cytoplasm under normal culture conditions. Nuclear accumulation of RanBP1 protein is used as a surrogate marker for CRM1 inhibition due to its ubiquitous expression and rapid CRM1-dependent shuttling (10) . We and other groups have previously reported the nuclear accumulation of RanBP1 induced by CRM1 inhibitors as observed by immunofluorescence microscopy (12, 40) . To confirm the inhibitory effect of MLN4924 against CBS9106, the subcellular localization of RanBP1 was analyzed when HCT116 cells were treated with MLN4924 and/or CBS9106 for 24 hours (Fig. 4) . RanBP1 localized to the cytoplasm in control (DMSO treated) and MLN4924-treated cells; however, CBS9106 or LMB treatment induced nuclear accumulation of RanBP1 (Fig. 4A) . Moreover, cotreatment of CBS9106 with MLN4924 prevented the nuclear localization of RanBP1 (Fig. 4A) . CRM1 protein is mainly localized in the nucleus in the control (DMSO treated) and MLN4924-treated cells. CBS9106 treatment reduced the overall level of CRM1 protein, and this response was prevented by adding MLN4924 (Fig. 4B) . The localization of RanBP1 and CRM1 by LMB was not affected by MLN4924. These results show that MLN4924 attenuates CBS9106-induced nuclear accumulation of RanBP1, as well as CRM1 degradation. Similar results were obtained for MM.1S cells ( Supplementary  Fig. S5 ).
Knockdown of NEDD8, UBA3, or Rbx1 prevents CRM1 degradation by CBS9106
To determine more directly whether CRM1 protein degradation is mediated by a neddylation pathway, siRNA knockdown experiments were performed in HCT116 cells to reduce the expression levels of NEDD8 or UBA3, two major effectors in the neddylation pathway or of Rbx1, an essential component of CRLs. As shown in Fig. 5A , knockdown of the endogenous NEDD8 remarkably inhibited cullin neddylation and CBS9106-induced CRM1 degradation. The knockdown of NEDD8 also stabilized p53 and cyclin B1 (Fig. 5A ). In addition, the expression levels of the SUMOylation proteins SUMO1 and SUMO2/3 were not affected (Fig. 5A) . Flow-cytometry analysis of control siRNAtransfected cells showed that the G 1 phase fraction increases significantly from 51.9% (Fig. 5B, lane 1) to 71.9% (Fig. 5B, lane 2 [from 47.9% (Fig. 5B, lane 7) to 54.5% (Fig. 5B, lane 8) ] upon 100 nmol/L CBS9106 treatment. These results indicate that CBS9106-induced G 1 phase cell-cycle arrest is suppressed, albeit partially, by reducing the level of NEDD8 protein.
Reducing the level of UBA3, an E1 component of the neddylation pathway, strongly inhibits the induction of CRM1 protein degradation by CBS9106 treatment (Fig.  5C) . Similarly, depletion of Rbx1 inhibits the CBS9106-induced degradation of CRM1 protein (Fig. 5D ). These findings suggest that CRL activity involving the neddylation pathway contributes to CBS9106-induced CRM1 protein degradation.
Knockdown of CSN5 and CAND1 partially inhibits CRM1 degradation by CBS9106 CRL activity is also regulated by cycles of CSN-mediated CRL deneddylation and CAND1 binding (25) (26) (27) . Depletion of CSN or CAND1 prevents the formation of CRL complexes and inhibits CRL activity (25) . CSN5 encodes the catalytic component of the CSN and knockdown of this molecule induces functional dysregulation of the CSN (30) (31) (32) . To investigate whether CRM1 protein degradation is mediated by CRLs, we knocked down CSN5 or CAND1 in HCT116 cells using siRNA. As shown in Fig. 6 , knockdown of the endogenous CSN5 or CAND1 partially inhibited CRM1 degradation by CBS9106. Deletion of CSN5 destabilizes Skp2 and leads to increased cullin neddylation. In turn, the destabilization of Skp2 reduces CRL activity. These findings suggest that CBS9106-induced CRM1 degradation is mediated by CRL activity involving the neddylation pathway.
Discussion
In the present study, we investigated how CBS9106 promotes the degradation of CRM1 protein. The seminal findings of this work are: (i) CBS9106-induced CRM1 degradation is inhibited by MLN4924; (ii) CBS9106-induced cell growth inhibition, apoptosis, and nuclear localization of RanBP1 are also inhibited by MLN4924; and (iii) knockdown of NEDD8, UBA3, or CRL-related proteins prevent CRM1 degradation by CBS9106. These findings indicate that CBS9106-mediated degradation of CRM1 is dependent on CRL activity involving the neddylation pathway.
MLN4924 is known to induce autophagy in multiple human cancer cell lines (37, 41, 42) . MLN4924-induced autophagy derives partially from the inhibition of mTOR activity, caused by accumulation of CRL substrates such as DEPTOR and HIF1a. Therefore, autophagy induced by MLN4924 may have led to its inhibitory effect against CBS9106 activity. However, low doses of MLN4924 were able to inhibit CBS9106 activity without inducing autophagy, and inhibitors of autophagy did not affect the reversal of CBS9106 activity by MLN4924 ( Supplementary  Fig. S6 ). MLN4924-induced autophagy was demonstrated by accumulation of HIF1a and degradation of p62 (37) . High doses of MLN4924-induced accumulation of HIF1a, but low doses of MLN4924 did not. Furthermore, the degradation of p62 was induced by high doses of MLN4924, but it was blocked by autophagy inhibitor 3-MA. Incidentally, p62 contains a nuclear export signal and shuttles between nuclear and cytoplasm. CRM1 inhibitor CBS9106 treatment induced stabilization of p62 in HCT116 cells. In addition, a variety of autophagy inhibitors, including 3-MA and bafilomycin A1 and mTOR inhibitor/autophagy activator CCI779, did not affect CBS9106-induced CRM1 degradation and RanBP1 nuclear accumulation (Fig. 2A, data not shown) . Therefore, we conclude that the inhibitory activity of MLN4924 against CBS9106-induced degradation of CRM1 is unrelated to autophagy.
Knockdown of Rbx1 protein by siRNA reversed CBS9106-induced CRM1 degradation (Fig. 5D ). This result indicates that CRM1 degradation caused by CBS9106 treatment depends on CRL activity. Cullin proteins complexes composed of seven cullin members do not have catalytic activity on their own, but instead serve as scaffolds that facilitate the assembly of multimeric E3 ligase complexes for transferring ubiquitin from E2-conjugating enzyme to its substrate (43) . To identify CRL components required for CRM1 degradation, siRNAmediated knockdown of each cullin component was performed. Notably, individual siRNA knockdown experiments for each of six cullin members (Cul1, 2, 3, 4A, 4B, and 5) had no effect on CRM1 degradation by CBS9106. Milhollen and colleagues (39) triple depletion of Cul1 and Cul4A/B is required to recapitulate the DNA rereplication phenotype observed with MLN4924 treatment. Therefore, the silencing of a single gene might not be sufficient to detect an inhibitory effect on induction of CRM1 degradation by CBS9106. Further analysis is, therefore, required to identify the cullins that are necessary for CBS9106-induced CRM1 degradation. NEDD8 can conjugate directly not only to cullins but also to other target proteins such as p53, pVHL, EGFR, and ribosomal proteins (44) (45) (46) . Protein neddylation occurs at lysine residues within target proteins and regulates its substrate activity. The CRM1 protein contains multiple lysine residues, and some of which are possible neddylation sites. 47, 48) . However, exogenously expressed CRM1 protein with a Lys to Ala point mutation at residue 139 (CRM1 K139A) was degraded as extensively as the wild-type (data not shown). Further studies will be needed to confirm whether the CRM1 protein is a substrate of neddylation.
The activity of CBS9106 mainly depends on an induction of the CRM1 degradation, but not completely. As shown in Figs. 3A and 4A, MLN4924 could not completely restore cell viability and nuclear shuttling activity even though MLN4924 prevents CRM1 degradation. In addition, MLN4924 could not completely suppress CBS9106-induced apoptosis in Fig. 3D and E. The implication is that CBS9106 exhibits residual anticancer activity without observable CRM1 degradation. Furthermore, CBS9106 and LMB bind to the same cysteine residue on the CRM1 protein, CBS9106 reversibly and LMB irreversibly. Sun and colleagues (49) showed that hydrolysis of LMB by CRM1 causes irreversible covalent conjugation. LMB, which is hydrolyzed, has no CRM1 degradation activity, but KPT-185, which is not hydrolyzed, has it. Like CBS9106, KPT-185 binds to CRM1 by reversible covalent conjugation and attenuates CRM1 protein (14) . Thus, the reversible reactivity against CRM1 may be related to the CRM1 degradation.
In conclusion, this study provides the first evidence that CBS9106-induced CRM1 degradation depends on CRL activity involving the neddylation pathway (Supplementary Fig. S7 ). As expected, MLN4924 attenuated tumor growth inhibition by CBS9106 in vivo in a preliminary xenograft experiment (Supplementary Fig. S8 ). This study indicates that inhibitors against the CRL-dependent proteasome pathway may reduce the efficacy of CBS9106. Importantly, CRM1 protein degradation plays important roles in CBS9106-induced responses such as cell growth inhibition and cell death. Therefore, the expression level of CRM1 protein appears to be a suitable surrogate marker for CBS9106 activity. 
